KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Profit After Tax (2018 - 2025)

Historic Profit After Tax for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $31.6 million.

  • Aurinia Pharmaceuticals' Profit After Tax rose 11986.76% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 44514.46%. This contributed to the annual value of $5.8 million for FY2024, which is 10737.25% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Profit After Tax stood at $31.6 million, which was up 11986.76% from $21.5 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Profit After Tax registered a high of $31.6 million during Q3 2025, and its lowest value of -$50.4 million during Q1 2021.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Profit After Tax value was -$13.4 million (recorded in 2023), while the average stood at -$15.0 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 9427.35% in 2021, then skyrocketed by 287963.99% in 2025.
  • Aurinia Pharmaceuticals' Profit After Tax (Quarter) stood at -$33.3 million in 2021, then grew by 21.84% to -$26.0 million in 2022, then dropped by 3.18% to -$26.9 million in 2023, then surged by 105.32% to $1.4 million in 2024, then surged by 2107.91% to $31.6 million in 2025.
  • Its Profit After Tax stands at $31.6 million for Q3 2025, versus $21.5 million for Q2 2025 and $23.3 million for Q1 2025.